Want to join the conversation?
$LRCX and $KLAC signed a definitive agreement, in which $LRCX will acquire all outstanding shares of $KLAC in a cash & stock transaction valued at $67.02 per share or $10.6Bil. Combined company will have approx. $8.7Bil in pro forma annual revenues & expect to generate about $600MM in incremental annual revenues by 2020.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.